Abstract 4365681: Cardiac adaptation to endurance exercise training requires suppression of GDF15 via PGC-1α

S Sumeet Khetarpal (Massachusetts General Hospital, Brookline, Massachusetts, United States) H Haobo Li (School of Chemical Engineering) T Tevis Vitale (Dana-Farber Cancer Institute, Boston, Massachusetts, United States) J James Rhee (Massachusetts General Hospital, Boston, Massachusetts, United States) S Saketh Challa (MGH, Boston, Massachusetts, United States) C Claire Castro (MGH- Cardiovascular Research Center, Boston, Massachusetts, United States) S Steffen Pabel (MGH- Cardiovascular Research Center, Boston, Massachusetts, United States) Y Yizhi Sun D Dina Bogoslavski A Ariana Vargas Castillo (Dana-Farber Cancer Institute, Boston, Massachusetts, United States) A Amanda Smythers K Katherine Blackmore L Louisa Grauvogel M Melanie Mittenbuhler (Dana-Farber Cancer Institute, Boston, Massachusetts, United States) M Melin Khandekar (Dana-Farber Cancer Institute, Boston, Massachusetts, United States) C Casie Curtin (Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States) C Chunyan Wang (Department of Oncology, School of Medicine and Public Health, University of Wisconsin) N Nicholas Houstis (Massachusetts General Hospital, Brookline, Massachusetts, United States) H Hans-Georg Sprenger (Dana-Farber Cancer Institute, Boston, Massachusetts, United States) S Sean Jurgens (Broad Institute and Amsterdam UMC, Amsterdam, Netherlands) K Kiran Biddinger (Massachusetts General Hospital, Brookline, Massachusetts, United States) A Alexandra Kuznetsov (Massachusetts General Hospital, Brookline, Massachusetts, United States) R Rebecca Freeman (Massachusetts General Hospital, Brookline, Massachusetts, United States) P Patrick Ellinor (The Broad Institute, Cambridge, Massachusetts, United States) M Matthias Nahrendorf (MGH- Cardiovascular Research Center, Boston, Massachusetts, United States) J Joao Paulo S Steven Gygi P Phillip Dumesic (Dana-Farber Cancer Institute, Boston, Massachusetts, United States) A Aarti Asnani (Beth Israel Deaconess, Arlington, Massachusetts, United States) K Krishna Aragam (Massachusetts General Hospital, Brookline, Massachusetts, United States) P Pere Puigserver J Jason Roh (Massachusetts General Hospital, Brookline, Massachusetts, United States) B Bruce Spiegelman (Dana-Farber Cancer Institute, Boston, Massachusetts, United States) A Anthony Rosenzweig (University of Michigan, Ann Arbor, Michigan, United States)

Abstract

Background/Significance: Exercise training induces physiological cardiac hypertrophy, mitochondrial biogenesis and myocardial function. In skeletal muscle, the transcriptional coactivator PGC-1α is a key orchestrator of these. The heart expresses abundant and exercise-responsive PGC-1α, but it is unclear whether this is necessary for cardiac adaptation to endurance training. Approaches: We utilize a genetic mouse model of cardiomyocyte PGC-1α deficiency along with somatic overexpression and knockdown of a PGC-1α related protein GDF15 using adeno-associated virus. We further utilize neonatal rat ventricular myocytes, human single nucleus RNA sequencing of patients with cardiomyopathies, and whole exome sequencing of human participants from the UK BioBank to address the relationship of PGC-1α with GDF15 and with cardiac dysfunction. Results: Wild-type and cardiomyocyte PGC-1α KO mice were subjected to voluntary wheel running for 5 weeks. Mice ran comparably over that time. Despite this, cardiomyocyte PGC-1α KO mice demonstrated no improvement in peak exercise capacity compared to WT mice (exercise work 33 J in WT vs 19 J in KO, p<0.001). Instead, PGC-1α KO mice demonstrated resting dilated cardiomyopathy after just 5 weeks of training (cardiac fractional shortening after training 60% in WT vs. 31% in KO, p<0.0001). Supporting this, extremely rare protein human genetic coding variants in PPARGC1A are associated with all-cause heart failure in the UK BioBank (RR 3.23, 95% CI 1.41-6.45, p=0.002). Cardiomyocyte PGC-1α-deficient trained hearts demonstrated absence of physiological hypertrophy (area 1170 vs. 555 μm 2 , p<0.0001) and markedly increased expression of the myomitokine GDF15 . GDF15 was secreted exclusively from cardiomyocytes but is not systemically elevated in PGC-1α-deficient mouse hearts. In cardiomyocytes, this occurs through the integrated stress response pathway, which is suppressed by PGC-1α overexpression. Cardiomyocyte-specific reduction of GDF15 preserves exercise tolerance, cardiac function, and exercise-induced cardiomyocyte hypertrophy in PGC-1α-deficient mice. We also find that cardiomyocyte PPARGC1A expression correlates with cardiomyocyte number and negatively with cardiomyocyte GDF15 expression in human cardiomyopathies through single nucleus RNA sequencing. Conclusions: Our data implicate cardiomyocyte PGC-1α as a vital enabler of physiological adaptation to endurance exercise through suppression of GDF15-mediated cardiac dysfunction.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (34)

S

Sumeet Khetarpal

Massachusetts General Hospital, Brookline, Massachusetts, United States

H

Haobo Li

School of Chemical Engineering

T

Tevis Vitale

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

J

James Rhee

Massachusetts General Hospital, Boston, Massachusetts, United States

S

Saketh Challa

MGH, Boston, Massachusetts, United States

C

Claire Castro

MGH- Cardiovascular Research Center, Boston, Massachusetts, United States

S

Steffen Pabel

MGH- Cardiovascular Research Center, Boston, Massachusetts, United States

Y

Yizhi Sun

D

Dina Bogoslavski

A

Ariana Vargas Castillo

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A

Amanda Smythers

K

Katherine Blackmore

L

Louisa Grauvogel

M

Melanie Mittenbuhler

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

M

Melin Khandekar

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

C

Casie Curtin

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

C

Chunyan Wang

Department of Oncology, School of Medicine and Public Health, University of Wisconsin

N

Nicholas Houstis

Massachusetts General Hospital, Brookline, Massachusetts, United States

H

Hans-Georg Sprenger

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

S

Sean Jurgens

Broad Institute and Amsterdam UMC, Amsterdam, Netherlands

K

Kiran Biddinger

Massachusetts General Hospital, Brookline, Massachusetts, United States

A

Alexandra Kuznetsov

Massachusetts General Hospital, Brookline, Massachusetts, United States

R

Rebecca Freeman

Massachusetts General Hospital, Brookline, Massachusetts, United States

P

Patrick Ellinor

The Broad Institute, Cambridge, Massachusetts, United States

M

Matthias Nahrendorf

MGH- Cardiovascular Research Center, Boston, Massachusetts, United States

J

Joao Paulo

S

Steven Gygi

P

Phillip Dumesic

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A

Aarti Asnani

Beth Israel Deaconess, Arlington, Massachusetts, United States

K

Krishna Aragam

Massachusetts General Hospital, Brookline, Massachusetts, United States

P

Pere Puigserver

J

Jason Roh

Massachusetts General Hospital, Brookline, Massachusetts, United States

B

Bruce Spiegelman

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A

Anthony Rosenzweig

University of Michigan, Ann Arbor, Michigan, United States